Home > Publications database > Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. > EndNote Text |
%0 Journal Article %A Zhao, Binghao %A Qi, Hao %A Wu, Jiaming %A Ma, Wenbin %T Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. %J Journal of thoracic oncology %V 18 %N 7 %@ 1556-0864 %C Amsterdam %I Elsevier %M DKFZ-2023-01257 %P e72 - e73 %D 2023 %Z #EA:D170# %F PUB:(DE-HGF)16 %9 Journal Article %$ pmid:37348996 %R 10.1016/j.jtho.2023.04.001 %U https://inrepo02.dkfz.de/record/277073